

The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma
Jorien B E Janssen 1,#, Cyrillo G Brahm 2,#, Chantal M L Driessen 3, Janine Nuver 4, Mariette Labots 5, Mathilde C M Kouwenhoven 6, Esther Sanchez Aliaga 7, Roelien H Enting 8, Jan Cees de Groot 9, Annemiek M E Walenkamp 10, Myra E van Linde 11, Henk M W Verheul 12,13,✉ Brain Commun. 2024 Jul 30;6(4):fcae241. doi: 10.1093/braincomms/fcae241 Abstract Previously, the tyrosine kinase inhibitor sunitinib failed to show clinical benefit in patients with recurrent glioblastoma.
소영 정
10월 13일2분 분량


Restrictive vs Liberal Transfusion Strategy in Traumatic Brain Injury A Secondary Analysis of the TRAIN Trial
Irene Sbaraini Zernini, MD1; Chiara Faso, MD1; Carla Bittencourt Rynkowski, MD, PhD2,3 et al 2026년09월08일 JAMA Neurol. Published online: September 8, 2026. DOI:10.1001/jamanetwokropen.2026.32555 Abstract Importance Anemia is a prevalent condition among patients with traumatic brain injury (TBI); however, the optimal hemoglobin (Hb) threshold to initiate red blood cell transfusion (RBCT) is not well defined. Objective To assess which of 2 different Hb thresholds for guidi
이정희
10월 7일4분 분량


Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial
Wolfgang Wick 1, Lisa-Marie Lanz 2, Antje Wick 3, Inga Harting 4, Susan Dettmer 2, Abigail K Suwala 5, Ralf Ketter 6, Ghazaleh Tabatabai 7 8, Corinna Seliger 3 9, Martin Glas 10, Michael C Burger 11, Marco Timmer 12, Florian A Ringel 13 14, Iris Mildenberger 15 16, Walter J Schulz-Schaeffer 17, Frank Winkler 3, Laila König 18, Christel Herold-Mende 19, Andreas Eisenmenger 2, Stefan M Pfister 20, Mirjam Renovanz 7 8 21, Martin Bendszus 4, Felix Sahm 22, Michael Platten 15 16,
소영 정
9월 15일3분 분량


Lifelong De Novo Aneurysm Risk After Aneurysmal Subarachnoid Hemorrhage in Young Survivors
Peter Alpkvist, MD1,2; Caroline Lindblad, MD, PhD1,2; Mikael Svensson, MD, PhD1,2 et alet al 2026년 8월24일 JAMA Neurol Published Online: August 24, 2026 DOI: 10.1001/jama.2026.2830 Abstract Importance Young survivors of aneurysmal subarachnoid hemorrhage (aSAH) risk de novo aneurysm formation, yet population-based lifetime estimates are lacking, and prior studies were limited by selection bias and short follow-up. Objectives To determine lifetime cumulative incidence, risk fa
이정희
9월 8일4분 분량


GLP-1 Receptor Agonist Use Is Associated With Lower Risk of Intracranial Aneurysm Rupture and Rupture Severity
Chen H, et al. et al Epub 2026 May 21 Stroke. 2026 Jul;57(7):1979-1990 DOI: 10.1161/STROKEAHA.126.055692 Abstract Background Unruptured intracranial aneurysms (UIAs) affect up to 5% of the population, and rupture can lead to devastating subarachnoid hemorrhage. GLP-1RAs (glucagon-like peptide-1 receptor agonists) have anti-inflammatory and vasculoprotective effects, but their impact on aneurysm stability and subarachnoid hemorrhage outcomes is unexplored. This study evalu
이정희
8월 24일3분 분량


Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Patrick Y. Wen, MD1 ; Donald A. Berry, PhD2 ; Meredith B. Buxton, PhD3 ; Howard Colman, MD, PhD, FAAN4 ; John de Groot, MD5 ; Michael Lim, MD6 ; Ingo Mellinghoff, MD7 ; James R. Perry, MD, FRCPC, FAAN8 ; Michael Weller, MD9 ; Nicholas A. Blondin, MD10; Omar H. Butt, MD, PhD, MS11 ; Denise M. Damek, MD12; Macarena I. de la Fuente, MD13 ; Jan Drappatz, MD14; Erin Dunbar, MD15; Pierre Giglio, MD16; Emma Viktoria Hyddmark, PhD3 ; Fabio Iwamoto, MD17; Kurt A. Jaeckle, MD18 ; Lyndo
소영 정
8월 18일3분 분량


Middle Meningeal Artery Embolization With n-Butyl Cyanoacrylate in Patients With Chronic Subdural HematomaA Randomized Clinical Trial
Christopher P. Kellner, MD1; Ansaar T. Rai, MD2; Hazem Shoirah, MD1 et alet al 2026년 6월 15일 JAMA Published Online: June 15, 2026 DOI: 10.1001/jama.2026.1542 Abstract Importance Middle meningeal artery embolization (MMAE) is a minimally invasive adjunctive treatment for chronic subdural hematoma (cSDH). The TRUFILL n-butyl cyanoacrylate (n-BCA) liquid embolic system is indicated for embolization of cerebral arteriovenous malformations for presurgical devascularization and may
이정희
8월 10일3분 분량


Cerebral Amyloid Angiopathy
Steven M. Greenberg, M.D., Ph.D 2026년 5월 6일 N Engl J Med 2026;394:1836-1845 DOI: 10.1056/NEJMra2411298 Summary Cerebral amyloid angiopathy is a major cause of hemorrhagic stroke, a frequent contributor to age-related cognitive impairment, and a key component in adverse responses to beta-amyloid (Aβ) immunotherapy. Defined by pathological deposition of Aβ in the small blood vessels of the brain, cerebral amyloid angiopathy is most often diagnosed on the basis of magnetic res
이정희
7월 29일4분 분량


Recent Advances and Future Prospects in Gene Delivery Platforms for Glioblastoma : A Review
1. Alexander F. Haddad, MD1; Rithvik Ramesh, BA1; Jorge Armando Peña Agudelo, PhD2,3 JAMA Neurol Published Online: July 13, 2026 doi: 10.1001/jamaneurol.2026.2131 Abstract Importance Glioblastoma (GBM) remains a disease with high mortality despite treatment with maximal safe surgical resection, radiation, and temozolomide. Standard of care for GBM has remained unchanged for decades. Gene therapies using both viral and nonviral platforms have the potential to significantl
소영 정
7월 20일2분 분량


Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers
Yael Rosen-Lang, MPH1; Agathe Vrillon, MD, PhD2,3; Shlomit Pasternak, MSc1 et al 2026년 06월 29일 JAMA Published Online: June 29, 2026 DOI: 10.1001/jamaneurol.2026.2042 Abstract Importance Traumatic brain injury (TBI) is a risk factor for dementia and is known to impact levels of several Alzheimer disease (AD) blood biomarkers. The plasma phosphorylated tau 217 (p-tau217)/amyloid-β 42 (Aβ42) ratio has been reported to be 90% accurate for the detection of brain amyloid in civili
이정희
7월 14일4분 분량


Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage
Craig S. Anderson, MBBS, PhD. et al. 2026년 4월 22일 N Engl J Med 2026;394:1571-1582 DOI: 10.1056/NEJMoa2515043 Abstract Background Blood-pressure reduction is the only proven treatment to prevent stroke due to intracerebral hemorrhage. Whether a single pill that combines three antihypertensive drugs at low doses, in addition to standard antihypertensive treatment, can lower blood pressure more than standard care alone and reduce the risk of recurrent stroke after intracereb
이정희
6월 29일3분 분량
Artificial intelligence-based MRI radiomics and radiogenomics in glioma
Haiqing Fan # 1, Yilin Luo # 1, Fang Gu 1, Bin Tian 1, Yongqin Xiong 1, Guipeng Wu 1, Xin Nie 1, Jing Yu 1, Juan Tong 1, Xin Liao 2 Affiliations Expand · PMID: 38486342 · PMCID: PMC10938723 · DOI: 10.1186/s40644-024-00682-y Abstract The specific genetic subtypes that gliomas exhibit result in variable clinical courses and the need to involve multidisciplinary teams of neurologists, epileptologists, neurooncologists and neurosurgeons. Currently, the dia
소영 정
6월 22일2분 분량


Endovascular Treatment of Medium-Vessel-Occlusion Strokes
Wei Hu, M.D et al. 2026년5월 13일 N Engl J Med 2016;394:1894-1904. DOI: 10.1056/NEJMoa2514120 Abstract Background Endovascular thrombectomy for acute ischemic stroke due to medium-vessel occlusion has had varying results across trials. Whether thrombectomy improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits is unclear. Methods We conducted an open-label, randomized trial with blinded outcome assessment at 48 centers in China.
이정희
6월 15일3분 분량


The glymphatic system and glioblastoma
Andrea Soumbasis 1,2, Aito Ueno 3,4,5,6, David Elliott 7,8,9, Sanju Lama 10,11,12,13, Sarah Edwards 14, Yves P Starreveld 15,16, Yunyan Zhang 17,18,19,20, Paolo Federico 21,22,23,24, Garnette R Sutherland 25,26,27,28, Pierre LeVan 29,30,31,32,33, Candice C Poon 34,35,36,37,38,39,✉ Brain. 2025 Nov 28;149(5):1485–1497. doi: 10.1093/brain/awaf449 Abstract The discovery of the glymphatic system and meningeal lymphatic vessels revolutionized the understanding of brain waste cleara
소영 정
6월 1일2분 분량


Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma
David Fiorella, M.D., Ph.D. et al. 2024년 11월 20일 N Engl J Med 2025;392:855-864 DOI: 10.1056/NEJMoa2409845 Abstract Background Patients receiving standard treatment for chronic subdural hematoma have a high risk of treatment failure. The effect of adjunctive middle meningeal artery embolization on the risk of treatment failure in this population remains unknown. Methods We randomly assigned patients with symptomatic chronic subdural hematoma to undergo middle meningeal art
이정희
5월 27일3분 분량


Peritumoral Edema in Gliomas: A Review of Mechanisms and Management
Kazufumi Ohmura 1,2 , Hiroyuki Tomita 1,3,* and Akira Hara 1 Biomedicines 2023, 11(10), 2731; https://doi.org/10.3390/biomedicines11102731 Submission received: 31 July 2023 / Revised: 29 September 2023 / Accepted: 6 October 2023 / Published: 9 October 2023 (This article belongs to the Special Issue Gliomas: Signaling Pathways, Molecular Mechanisms and Therapeutic Approaches) Abstract: Treating malignant glioma is challenging owing to its highly invasive potential in he
소영 정
5월 19일2분 분량


Management of Chronic Subdural Hematoma With Adjunctive Embolization of Middle Meningeal Artery The EMMA-Can Randomized Clinical Trial
Jai Jai Shiva Shankar, MD, DM, MSc1,2,3; Susan Alcock, MN1; Nima Kashani, MD1et al 2026년04월30일 JAMA Neurol. Published online: April 30, 2026. DOI:10.1001/jamaneurol.2026.4910 Importance Chronic subdural hematomas commonly recur after surgical drainage. The effect of adjunctive embolization of the middle meningeal artery (EMMA) on recurrence risk remains unclear. Objective To evaluate whether EMMA as an adjunct to surgical drainage reduces chronic subdural hematoma recurrenc
이정희
5월 8일3분 분량


Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus
Stefano Meletti, MD, PhD1,2; Aurelie Hanin, PhD3,4; Giada Giovannini, MD, PhD1 et al 2026년04월27일 JAMA Neurol. Published online: April 27, 2026. DOI:10.1001/jamaneurol.2026.0865 Abstract Importance Seizure-induced brain injury is central to the treatment urgency of new-onset refractory status epilepticus (NORSE). Identifying biomarkers that reflect ongoing neuronal damage could inform therapeutic timing and improve outcomes. Objective To quantify acute brain injury in pati
이정희
4월 28일4분 분량


Tumor microenvironment in glioblastoma: Current and emerging concepts
Pratibha Sharma , Ashley Aaroe, Jiyong Liang, and Vinay K. Puduvalli Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (P.S., A.A., J.L., V.K.P.) Corresponding Author: Vinay K. Puduvalli, MD, 1515 Holcombe Blvd, Unit 431, Houston, TX 77030, USA (vpuduval@mdanderson. org). Neuro-Oncology Advances 5(1), 1–16, 2023 | https://doi.org/10.1093/noajnl/vdad009 | Advance Access date 23 February 2023 Glioblastoma (GBM) tumor microenvir
소영 정
4월 27일2분 분량


Long-Term Mortality, Cognition, and Quality of Life After Chronic Subdural Hematoma Surgery
Thomas Petutschnigg, MD1 ; Samuel Aschwanden1 ; Claire Descombes, MSc1 et al 2026년 04월13일 JAMA Neurol . Published online: April 13, 2026. Doi: 10.1001/jamaneurol.2026.0656 Abstract Importance Chronic subdural hematoma (cSDH) is among the most common neurosurgical disorders in older adults. Although short-term outcomes after surgery are favorable, long-term survival and health-related quality of life (HRQoL) remain poorly characterized. Objectives To evaluate long-t
이정희
4월 20일4분 분량




